Literature DB >> 4519131

Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris).

C Jacquillat, M Weil, M F Gemon, G Auclerc, J P Loisel, J Delobel, G Flandrin, G Schaison, V Izrael, A Bussel, C Dresch, C Weisgerber, D Rain, J Tanzer, Y Najean, M Seligmann, M Boiron, J Bernard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4519131

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  7 in total

Review 1.  Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

2.  Prognosis and treatment of acute lymphoblastic leukemia. Study of 650 patients.

Authors:  C Jacquillat; M Weil; M F Auclerc; C Chastang; G Flandrin; V Izrael; G Schaison; L Degos; M Boiron; J Bernard
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 3.  Progress of minimal residual disease studies in childhood acute leukemia.

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

4.  Combination chemotherapy for acute lymphocytic leukaemia in 25 adults.

Authors:  E G de Vries; N H Mulder; B Houwen; H Haaxma-Reiche
Journal:  Blut       Date:  1982-03

5.  Adult acute leukaemia.

Authors:  K Atkinson; D G Wells; H M Clink; H E Kay; R Powles; T J McElwain
Journal:  Br J Cancer       Date:  1974-09       Impact factor: 7.640

6.  Treatment of childhood lymphocytic leukaemia with high white-cell counts.

Authors:  H Ekert; K D Waters; P J Smith; R N Matthews; W M Ellis
Journal:  Br J Cancer       Date:  1978-11       Impact factor: 7.640

7.  Childhood acute leukaemia in a tropical population.

Authors:  C K Williams; A O Folami; A A Laditan; E O Ukaejiofo
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.